The global Ankylosing Spondylitis Market is expanding as awareness and diagnosis of chronic inflammatory spinal disorders increase and patients gain greater access to advanced therapies. Ankylosing spondylitis is a long-term inflammatory disease primarily affecting the spine and joints, creating sustained demand for pain-management, anti-inflammatory, biologic, and targeted therapies. Increasing adoption of TNF inhibitors, interleukin inhibitors, biosimilars, oral small-molecule therapies, precision medicine, and digital disease-management solutions is further supporting market development.

According to Fortune Business Insights, the global ankylosing spondylitis market was valued at USD 6.83 billion in 2025 and is projected to grow from USD 7.28 billion in 2026 to USD 12.05 billion by 2034, exhibiting a CAGR of 6.51% during the forecast period.

Why is the Ankylosing Spondylitis Market Growing?

The increasing prevalence of autoimmune and inflammatory disorders, combined with improved disease awareness and diagnosis, is a major factor driving the market. Ankylosing spondylitis often requires long-term disease management involving anti-inflammatory medicines, biologic therapies, rehabilitation, and physiotherapy.

Treatment options are increasingly being used for:

• Spinal inflammation and stiffness
• Chronic back pain
• Joint inflammation
• Reduced mobility
• Severe inflammatory disease
• Patients unresponsive to conventional treatments
• Long-term disease management
• Rehabilitation and mobility support

Growing access to specialty rheumatology services and biologic treatments is also expanding the addressable patient population.

Key Market Trends Shaping Industry Growth

Increasing Adoption of Biologic Therapies

Biologic therapies are becoming increasingly important in ankylosing spondylitis management. TNF inhibitors and interleukin inhibitors are being increasingly used for patients with significant inflammation and inadequate response to conventional therapies.

Growing Adoption of Biosimilars

Biosimilars are gaining attention because they can improve access to advanced biologic therapies while potentially reducing treatment costs. Pharmaceutical companies are increasing investment in biosimilar development, especially for emerging healthcare markets.

Increasing Focus on Interleukin Inhibitors